# A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02175784` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02175784](<https://clinicaltrials.gov/study/NCT02175784>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02175784

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 262 participants.

## Technical summary

Registry record NCT02175784. Randomized; quadruple masking; primary purpose treatment. Start 2014-03-31 (actual); primary completion 2015-03-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 262 participants (enrolled count; ClinicalTrials.gov record NCT02175784, source copy `cardio:ctgov-nct02175784-2024-11-08`, retrieved 2026-10-26)
- Started: 2014-03-31 (actual) (ClinicalTrials.gov record NCT02175784, source copy `cardio:ctgov-nct02175784-2024-11-08`, retrieved 2026-10-26)
- Primary completion: 2015-03-31 (actual) (ClinicalTrials.gov record NCT02175784, source copy `cardio:ctgov-nct02175784-2024-11-08`, retrieved 2026-10-26)
- Completion: 2015-12-07 (actual) (ClinicalTrials.gov record NCT02175784, source copy `cardio:ctgov-nct02175784-2024-11-08`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02175784, source copy `cardio:ctgov-nct02175784-2024-11-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02175784-2024-11-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): ipragliflozin
- Intervention (Drug): placebo
- Lead sponsor: Astellas Pharma Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: ff140ecd10e044bacdc580cacf569b6859b278b4270d940efdbcf6d6ba7a0d1e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
